Half Year Results

The strong uptake of the newly launched products show the value of scientific innovation for patients, bringing real progress in areas with significant unmet medical need.

Boehringer Ingelheim reports first-half 2026 sales growth

Survodutide Phase III trial shows 34% visceral and 63% liver fat reduction while minimizing lean mass loss

News & Stories

Planning certainty is the foundation for innovation

Reliable framework conditions secure investment, progress and supply in Germany.

Cities teaming up to enhance stroke care

Discover how Angels Cities build collaborations to act quickly on stroke symptoms.

Social impact investing in Africa

With our support, Farm Alert, a social enterprise founded by a Nigerian veterinarian, is making social impact and transforming animal care in West Africa.

Understanding biomarker testing in lung cancer

Knowing biomarker status is essential for informed healthcare decisions.

Helping Ecuador fight rabies

Discover how we're planting the seeds of change in the next generation through our Stop Rabies program.

A call for integrated care to tackle the deadliest group of diseases

NCDs are the deadliest group of diseases. At the 80th UN General Assembly, we’re calling for integrated care of CRM conditions.

Working at Boehringer Ingelheim

Join us to grow, collaborate, innovate and improve lives.